Covid-19 Manufacturing Roundup: Thermo Fisher plant ramps up AstraZeneca vaccine production; Novavax expands Korean manufacturing pact
Shortly after Thermo Fisher’s $878.2 million buyout of Novasep’s viral vector manufacturing business, it took over a plant in Belgium tasked with producing adenovirus vectors for AstraZeneca’s version of the Covid-19 shot.
That production agreement was instigated when Novasep was still in charge, and the plant shouldered much of the blame for the oft-publicized slowdown of vaccine output in recent weeks. Now that Thermo Fisher has taken over, though, the plant has “drastically” ramped up its production of late, Reuters reported Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.